Although the transcription factor USF2 has been implicated in the regulation of cellular growth and proliferation, it is unknown whether alterations in USF2 contribute to tumorigenesis and tumor development. We examined the role of USF2 in prostate tumorigenesis. Western blot analysis revealed markedly decreased USF2 levels in three androgen-independent prostate cancer cell lines, PC-3, DU145, and M12, as compared to nontumorigenic prostate epithelial cells or the androgen-dependent cell line, LNCaP. Ectopic expression of USF2 in PC-3 cells did not affect the cell proliferation rate of PC-3 cells on plastic surfaces. However, it dramatically decreased anchorage-independent growth of PC-3 cells in soft agar (90-98% inhibition) and the invasion capability (80% inhibition) of PC-3 cells in matrix gel assay. Importantly, expression of USF2 in PC-3 cells inhibited the tumorigenicity of PC-3 cells in an in vivo nude mice xenograft model (80-90% inhibition). These results suggest that USF2 has tumor-suppression function. Consistent with its function in tumor suppression, we found that the USF2 protein is present in normal prostate epithelial cells but absent in 18 of 42 (43%) human prostate cancer tissues (P ¼ 0.015). To further examine the functional role of USF2 in vivo, we generated mice with genetic deletion of USF2 gene. We found that USF2-null mice displayed marked prostate hyperplasia at a young age, suggesting that USF2 is involved in the normal growth and differentiation of prostate. Together, these studies demonstrate that USF2 has tumor-suppressor function and plays a role in prostate carcinogenesis.
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Introduction
Transcription factor upstream stimulatory factor (USF) was originally identified as a cellular transcription factor important for expression of the adenovirus major late promoter (Sawadogo and Roeder, 1985) . USF is structurally related to the Myc oncoproteins and belongs to the basic-helix-loop-helix-leucine zipper (bHLH-zip) group of transcriptional regulators (Sawadogo and Roeder, 1985; Gregor et al., 1990; Bendall and Molloy, 1994) . In mammals, USFs are encoded by two different genes, Usf1 and Usf2, and these genes are ubiquitously expressed (Luo and Sawadogo, 1996b; Sawadogo, 1988) . USF1 and USF2 form either hetero-or homodimers to bind to CACGTG sequences (E-boxes) in the promoters of their target genes.
USF2 has been shown to be an important regulator of normal development. USF2-null mice are much smaller than their wild-type (WT) littermates, and remain smaller throughout their lifetimes (Sirito et al., 1998) . In all, 50% of USF2-null mice die shortly after birth, while mice lacking both USF1 and USF2 die during early embryogenesis (Sirito et al., 1998) . In vitro experiments also revealed a role of USF in regulating cellular proliferation and growth. Transfection of either USF1 or USF2 inhibited cellular transformation induced by c-Myc or activated Ras in primary rat embryo fibroblasts (REFs). USF2 also inhibited E1A-mediated transformation in REFs, while USF1 did not, suggesting that USF2 has a broader inhibitory function (Luo and Sawadogo, 1996a) . Consistent with these observations, USF transcriptional activity was detected in nontumorigenic cells, but not in many cancer cells (e.g., Saos-2 and MCF-7) Qyang et al., 1999) . Although these findings suggest that USF2 has antitumorigenic functions, there is no direct evidence that USF2 plays a role in human cancer.
The USF2 gene is located at Chr 19q13 (Steingrimsson et al., 1995) . Loss of Chr19q ter-q13.1 has been demonstrated in half of the hormone refractory prostate cancer samples (Nupponen et al., 1998) . Reintroduction of an intact human chromosome 19 into a tumorigenic prostate cell line lacking one copy of the short arm and proximal long arm of .1) significantly reduced tumorigenicity in athymic nude mice (Astbury et al., 2001) . These findings indicate the presence of tumor-suppressor genes for prostate cancer within the Chr 19q region. In addition, USF2 has recently been found to be part of the prostatic factor complex as an androgen receptor cofactor (Kivinen et al., 2004) . Alterations of the oncogenes, c-myc and ras, and the tumor-suppressor genes, APC, BRCA2, and p53, have been implicated in prostate cancer (Davis et al., 1999; Gao and Honn, 1999; Karayi and Markham, 2004) . Interestingly, not only does USF interfere with the transformation of REFs by Ras and c-Myc (Aperlo et al., 1996; Luo and Sawadogo, 1996a) , but USF2 also regulates expression of the APC, BRCA2, and p53 genes, all of which contain in their promoters E-boxes that bind USF (Reisman and Rotter, 1993; Davis et al., 1999; Jaiswal and Narayan, 2001) . Taken together, these data suggest that USF2 is involved in prostate cancer progression, so we investigated a possible role of USF2 in prostate carcinogenesis. We found that USF2 was downregulated in human prostate cancer specimens. Re-expression of USF2 in USF2-deficient prostate cancer cells inhibited the tumorigenicity in an in vivo xenograft model. Furthermore, deletion of USF2 by gene knockout caused prostate hyperplasia in USF2-null mice. These observations suggest that USF2 plays a tumor-suppression role in prostate carcinogenesis.
Results

USF2 protein levels in human prostate cancer cell lines
To address the relationship of USF2 with prostate cancer, we first investigated the endogenous expression of USF2 in several prostate cancer cell lines: PC-3, DU145, LNCaP, and M12. As human and mouse USF2 are 97% identical in amino-acid sequence, and the USF2 antibody recognizes both proteins (Sirito et al., 1994) , whole-cell lysates from WT and USF2-null MEFs served as controls for antibody specificity. Equal amounts of protein were loaded onto SDS-PAGE. USF2 was strongly expressed in three nontumorigenic prostate cell lines, RWPE1, P69, and F611 (Bae et al., 1994; Bello et al., 1997; Astbury et al., 2001) , and also in LNCaP, an androgen-dependent prostate cancer cell line with weaker tumorigenic potential than PC-3 and DU145 (Kozlowski and Sensibar, 1999) . The robust USF2 expression in the nontumorigenic prostate cancer cell lines was similar to that in the nontumorigenic breast epithelial cell line MCF10A (Figure 1 ). In contrast, three androgen-independent cell lines, PC-3, DU145, and M12 (Kozlowski and Sensibar, 1999; Plymate et al., 2004) , expressed considerably less USF2 ( Figure 1 ). As the PC-3 cell line is a wellcharacterized prostate cancer cell line (Kozlowski and Sensibar, 1999) with low USF2 expression, we selected it to study the effects of USF2 on tumorigenicity of prostate cancer cells.
Constitutive USF2 expression in PC-3 cells does not affect growth rate or apoptosis in two-dimensional culture To investigate the function of USF2 in PC-3 cells, we generated PC-3 cell lines with stable expression of USF2. Among antibiotic-resistant clones, we identified several USF2-expressing subclones and non-USF2-expressing subclones (Figure 2a) . Despite constitutive expression, all USF2-transfected clones grew well in culture. The MTT assay revealed similar growth rates on plastic dishes for all cell lines tested: two USF2-expressing clones (C9 and C11) and three controls (two without USF2, C3, and C27, and the parental cell line) (Figure 2b ). Similar results were obtained by counting cell numbers (data not shown). BrdU incorporation, which occurs specifically during DNA synthesis in S phase and is a more sensitive assay for detecting proliferation, did not reveal a significant difference in proliferation between the USF2-expressing clone, C9 (26.2%), and the control clone, C27 (25.2%) (Figure 2c) .
A previous study by using flow cytometry analysis showed that transient expression of USF2 in prostate cancer cells did not cause apoptosis (data not shown). Similarly, the annexin V assay revealed no significant differences in the levels of either apoptosis or necrosis between PC-3 subclones with (C9) or without (C27) USF2 expression (Figure 2d ). Taken together, these results indicated that USF2 does not affect the cell Tumor-suppressor role of USF2 in prostate cancer N Chen et al proliferation rate in cycling cells and that USF2 overexpression is not toxic to cells.
USF2 expression inhibits the malignant properties of PC-3 cells in vitro
We next investigated the effect of USF2 on tumorigenic features of PC-3 cells using the stable USF2-expressing subclones and control clones. We first studied the effect of USF2 on the colony-forming ability of PC-3 cells in soft agar, since anchorage-independent growth is an important property of tumor cells (Ruddon, 1995) . In the soft agar assay, USF2-expressing clones, C9, C11, and C18, formed notably fewer colonies than did the control clones or the parental cell line (Figure 3a and b) . Furthermore, the sizes of the colonies formed by USF2-expressing cells were much smaller than those formed by the control clones ( Figure 3b ). We further assessed the effect of USF2 on invasive ability of cells using the Matrigel chamber assay. We found that the ability of PC-3 cells to digest and penetrate the Matrigel barrier is attenuated in USF2-expressing clones (80% inhibition of invasion) (Figure 3c ), suggesting that expression of USF2 inhibited the invasive ability of PC-3 cells.
USF2 expression inhibits the tumorigenicity of PC-3 cells in vivo Next, we examined the effect of USF2 on tumor growth in vivo by injecting PC-3 cells into nude mice subcutaneously. To effectively compare the tumorigenicity of the USF2-expressing and control clones, each mouse was injected with a control clone and a USF2-expressing clone, one on each side. One group of mice received USF2-expressing clone C9 and control clone C27, and the other group received USF2-expressing clone C11 and control clone C3. Three out of five mice in each group developed tumors. In all cases, the tumors derived from USF2-expressing clones were much smaller than those from the control clones (Figure 4 ). At week 10 after injection, the average tumor size from USF2-expressing clone C9 was 0.24870.065 cm 3 , as compared to 1.20970.055 cm 3 for the control clone C27 (P ¼ 0.001). For USF2-expressing clone C11 and the control clone C3, the average tumor sizes were 0.04870.017 and 0.54770.067 cm 3 , respectively (P ¼ 0.0093). These results demonstrated that expression of USF2 markedly inhibits the tumorigenicity of PC-3 cells in vivo.
Functional domains of USF2 required for activity in PC-3 cells We further examined whether the tumor-suppressive activity of USF2 is related to its function as a transcription factor. Various deletion mutants of USF2 were transfected into PC-3 cells, and their ability to activate transcription of the reporter gene was analysed ( Figure 5a ). As shown in Figure 5c , deletion of the entire Tumor-suppressor role of USF2 in prostate cancer N Chen et al N-terminus (DN), the basic region (DBR), or the USFspecific region (DUSR) markedly decreased the ability of USF2 to activate transcription in PC-3 cells, while deletion of the exon 5-encoded domain (DE5) did not ( Figure 5c ). The differences in transcriptional activity were not due to protein levels, as similar amounts of USF2 proteins were expressed in both mutant and WT USF2-transfected cells (Figure 5b ). The ability of the USF2 mutants to inhibit colony formation of PC-3 cells was examined. As shown in Figure 5d , mutants lacking transcriptional activity were significantly impaired in their abilities to inhibit colony formation of PC-3 cells (Figure 5d ). Mutant DBR was essentially inactive, indicating that DNA binding by USF2 was critical for inhibiting colony formation in PC-3 cells. At least two additional domains, including the USR and another domain located at the DN, were also required for full activity in PC-3 cells since both DUSR and D(7-199), which retains the USR, were inactive. Deletion of exon 5-encoded region (mutant DE5) in USF2 had little effect on colony formation compared to the WT USF2, suggesting that the DE5 is not critical for USF2's tumorsuppressive activity. These observations reveal a correlation between USF2's tumor-suppressive activity and its transcriptional activity.
USF2 was downregulated in human prostate cancer tissues
Our data demonstrated that expression of USF2 inhibited the tumorigenicity of PC-3 cells both in vitro and in vivo. To verify the role of USF2 in human prostate cancer, we examined USF2 protein expression in human prostate cancer tissues. In total, 42 prostate adenocarcinoma, 10 prostate intraepithelial neoplasia (PIN), and 11 normal prostates were examined by immunohistochemistry. Immunohistochemical analysis of prostate cancer tissue arrays revealed that USF2 was expressed in most epithelial and stromal cells of all normal prostate samples (n ¼ 11) (Figure 6a ), but was undetectable in 18 of 42 prostate cancer samples (43%) (Figure 6c and Table 1 ) (P ¼ 0.015 vs normal). Of 42 prostate cancer tissue samples, 20 (48%) expressed USF2 at heterogeneous or low levels (Figure 6d) . Overall, 91% of prostate cancer samples expressed USF2 at low or negative levels, while eight of 10 samples (80%) with PIN displayed low or negative USF2 expression (Figure 6b and Table 1 ) (P ¼ 0.0001 vs normal). These data demonstrate that downregulation of USF2 protein occurs in most prostate cancer tissues, suggesting that USF2 may play a role in prostate cancer progression. Knockout of USF2 gene results in hyperplasia in mouse prostates To obtain additional evidence for a causal relationship between USF2 loss and carcinogenesis, we examined mice with a germ-line mutation of USF2. On average, male USF2-null mice have markedly shorter lifespans (3-6 months) than females (2 years) (Sirito et al., 1998) . We examined the prostates of age-matched USF2-null mice and control WT mice. In all, 13 USF2-null and 10 WT mice with an average age of 23 weeks (range: 11-41 weeks) were analysed. WT mice showed normal architecture of prostatic ducts lined by a single layer of flattened epithelial cells with small basal nuclei (Figure 7a, b) . In contrast, 10 of 13 USF2-null mice (77%) displayed obviously focal or broad areas of epithelial and stromal hyperplasia. Many papillary projections and stratification were present in the hyperplastic ducts (Figure 7c-f) , and marked alteration in the USF2-null mice prostates can be observed in mice as young as 11-weeks old (Figure 7c ). In four of 13 null mice (30%), we also observed hyperplasia with focal atypical epithelial cells evidenced by enlarged nuclei, hyperchromatia, and prominent nucleoli (Figure 7e, f) , which are characteristic preneoplastic alterations (Shappell et al., 2004) . We blindly quantified the number 
arrow). (c) and (c). Representatives of prostate adenocarcinomas, where USF2 staining is undetectable (c) or heterogeneous (d, arrow).
Tumor-suppressor role of USF2 in prostate cancer N Chen et al of prostate ducts with abnormal ductal epithelia in each mouse. In the WT control mice, only a very few ducts with abnormal ductal epithelium (3.3%) were observed. However, 18.8% of total ducts in USF2-null mice had hyperplasia (P ¼ 0.0003) ( Table 2) . Although hyperplasia is not prostate cancer, these data indicate that there is dysregulated prostate growth in USF2-null mice.
Discussion
In the present work, we investigated the role of USF2 in prostate tumorigenesis. Several lines of evidence indicate that USF2 has tumor-suppressive activity. First, restoration of USF2 in the USF2-deficient prostate cancer cell line PC-3 strongly suppresses tumorigenic features of PC-3 cells. In addition, USF2 protein is absent or decreased in most prostate cancer tissues and cell lines. Furthermore, deletion of the USF2 gene in mice results in prostatic epithelial hyperplasia at an early age.
The mechanisms by which a tumor-suppressor gene is inactivated are complex and may include alterations in tumor-suppressor gene regulation that in turn lead to changed protein levels. USF2 protein level is downregulated in many prostate cancer tissues and cell lines (Figures 1 and 5 ), but we detected no mutations in the Tumor-suppressor role of USF2 in prostate cancer N Chen et al USF2 gene. Although tumor-suppressor genes were originally defined as genes that are deleted or mutated in human cancer cells (Macleod, 2000) , most tumorsuppressor genes, in fact, have low mutation or deletion incidences in prostate cancer. For example, loss at the Rb locus occurs in only 23 to 35% of cases (Gao and Honn, 1999) , and mutation of p53, the most commonly mutated gene in human malignancies, occurs at the low frequency of 10-22% in prostate cancer (Gao and Honn, 1999; Isaacs and Kainu, 2001; Karayi and Markham, 2004) . Mutations of CDKN1B, the gene coding p27
Kip1 , are also rare (35). Moreover, like the USF2 gene, the coding region of the NKX3.1 prostatespecific tumor-suppressor gene has no mutations (Voeller et al., 1997) , even though the protein is downregulated in 34% of hormone-refractory prostate cancers and 78% of metastases (Bowen et al., 2000) . Thus, downregulation of the proteins that have tumorsuppressive function constitutes one of the major mechanisms in prostate tumorigenesis. Using comparative genomic hybridization (CGH), Nupponen et al. (1998) reported loss of chr19 in almost half of the hormone refractory prostate cancer samples. As CGH assay detects chromosomal copy number changes (loss or gain), the loss of chr19 does not mean that all gene copies are lost or that there are necessarily mutations on the gene. Furthermore, it is possible that regulatory regions of the USF2 gene have been altered in some prostate cancers, possibly through a chromosomal translocation that separated the coding USF2 region from a regulatory element such as enhancer or promoter. Therefore, it is reasonable that we can detect the USF2 gene and that no mutation was found.
In the USF2-null mice, we observed that inactivation of USF2 protein resulted in prostate epithelial cell hyperplasia as early as 11 weeks of age (Figure 7b ). Owing to the short lifespan of the male USF2 gene knockout mice, it is not clear whether the epithelial cell hyperplasia can be further developed into prostate cancer in older age. To overcome this limitation, it may be necessary to produce prostate-targeted USF2 knockout mice. In any event, our finding that the germline knockout of USF2 results in a prostatic preneoplastic phenotype indicates that loss of USF2 is involved in human prostate carcinogenesis. Such findings are consistent with observations from other tumor-suppressor gene-inactivated animal models. For example, although the conditional deletion of Rb in the mouse results only in proliferation of prostate epithelial cells at an early age, no evidence of malignant lesion was observed until a later age (Maddison et al., 2004) . Mice deficient in NKX3.1 developed prostatic hyperplasia and dysplasia, but no tumors developed in the prostate (Bhatia-Gaur et al., 1999) . p27 knockout mice are also tumor free, but display enhanced malignancy and frequency of tumor formation with different oncogenic stimuli (Blain et al., 2003) . All these findings suggest that additional molecular events are required to develop prostate malignant transformation (Bookstein, 2001) .
Unlike many tumor-suppressor genes, including p53, pTEN, and pRb, which inhibit tumorigenicity by inhibiting cell growth and/or inducing apoptosis (Gao and Honn, 1999) , USF2 expressed in PC-3 cells had no detectable effect on cell growth and apoptosis in 2-dimensional culture (Figure 2 ). This result suggests that mechanisms other than induction of apoptosis are involved in the tumor-suppressing function of USF2. One possible mechanism is that USF2 may inhibit tumorigenesis by regulating many cancer-and proliferation-associated genes such as Cox-2, BRCA2, cathepsin D, APC, IGF2R, p53 and CDK4, etc. (Davis et al., 1999; Szentirmay et al., 2003; Pawar et al., 2004) , and their corresponding signal transduction pathways. This possibility is supported by our observation that USF2-suppression function correlates with its transcriptional activity. Future investigations of genes whose expression is regulated by USF2 in prostate cancer will be important in determining the mechanism of USF2's tumor-suppressive function. A second possible mechanism is that USF2 is involved in regulation of the androgen receptor, which is suggested by the observation that USF2 is a cofactor of androgen receptors (Kivinen et al., 2004) . In agreement with this finding, we have observed that the androgen-dependent cell line LNCaP expresses a higher level of USF2 than the androgen-independent cell lines, PC-3, DU145, and M12 (Figure 1) . Moreover, the phenotypes of the USF2-null mice are significantly different between males and females, in that male mice die early and are infertile (Sirito et al., 1998) . As the androgen receptor plays a critical role in prostate cancer development (Gonzalgo and Isaacs, 2003; Dehm and Tindall, 2005) , elucidating the relationship between USF2 and the androgen receptor will be of clinical significance and is currently under investigation.
Materials and methods
Cell culture
The prostate cancer cell lines PC-3, DU145, and LNCaP were propagated at 371C with 5% CO 2 in complete RPMI 1640 medium supplemented with 10% fetal bovine serum. RWPE-1 and its special medium were from the ATCC. The nontumorigenic prostate cell lines P69 and F611 and all other cell lines were cultured as previously described (Bae et al., 1994; Ismail et al., 1999) . All cell lines, including USF2 stable clones, were tested by MycoAlert (Cambrex Bio Science Rockland Inc.) to ensure that there was no mycoplasma contamination.
Whole cell extracts and Western blotting Cells grown exponentially were harvested for whole-cell extracts (Pawar et al., 2004) . Equal amounts of protein per lane were loaded on 12% SDS-PAGE gels, transferred to membranes, and analysed using antibodies against USF2 (N-18) (Santa Cruz) and b-actin (Sigma) (Pawar et al., 2004) .
Stable USF2-expressing PC-3 cell lines and cell proliferation assay Stable USF2-expressing cell lines were generated following the protocol described previously (Choe et al., 2005) . Cells were seeded in 96-well plates (2000 cells/well). At different times, 50 ml of 2 mg/ml tetrazolium bromide (MTT, Sigma) were Tumor-suppressor role of USF2 in prostate cancer N Chen et al added to each well. After 4 h, the medium was discarded and 100 ml of DMSO added to dissolve the formazan crystals. The plates were read at 540 nm in a multiwell reader. As mitochondrial dehydrogenase from viable cells is able to cleave the tetrazolium rings of the yellow MTT and form formazan crystals, the level of the dark blue formazan product directly represents the number of surviving cells (Mosmann, 1983) .
BrdU incorporation assay Cells in exponential growth were pulsed with 10 mM bromodeoxyuridine (BrdU, Sigma) 45 min before harvesting. Harvested cells were fixed in ethanol, permeabilized by incubation in 2 M HCl with 0.5% (v/v) Triton X-100 and incubated in blocking buffer (0.5% Triton X-100 and 4% BSA in PBS) for 30 min, followed by an 1 h incubation in mouse anti-BrdU antibody (BD) (1:10 dilution in blocking buffer). The cells were washed and incubated in goat-anti-mouse IgG wholemolecule FITC conjugate (Sigma) (1:50 dilution in blocking buffer), then in PBS containing 20 mg/ml propidium iodide (PI) and 200 mg/ml RNase A (Sigma). The samples were analysed on a Coulter flow cytometer XL-MCL (Coulter Corporation).
Annexin V assay and cell cycle analysis Apoptotic cells were detected using the Annexin-V-FLUOS staining kit (Roche) according to the manufacturer's instructions. For cell cycle analysis, the harvested cells were fixed in 70% ethanol, washed with PBS, and resuspended in PBS containing 50 mg/ml of RNase A and 50 mg/ml PI.
Anchorage-independent growth assay in soft agar Soft agar experiments were performed in six-well plates (Choe et al., 2005) . The 2.5-ml bottom layer contained 1% SeaKem agarose in complete medium and the top layer (1.5 ml) contained 0.6% SeaPlaque low melting agarose in complete medium and 4000 cells. The plates were cultured at 371C with 5% CO 2 for 6 weeks. The plates were photographed, and the number of colonies in each well was counted under the microscope.
Nude mouse tumorigenicity studies Cells in exponential growth were harvested, washed, resuspended on ice in 0.2 ml of FBS-free RPMI 1640, and subcutaneously injected into the flanks of 5-week-old male athymic mice (five mice for each cell line, Charles River Laboratories). The trypan blue exclusion assay was used to ensure cell viability (>99%) before and after injection. For direct comparison, each mouse was injected with two different cell clones (9 Â 10 6 /each injection), one on each side. Tumor sizes were measured with calipers every week until the largest tumor reached a length of 1.5 cm. Tumor volumes were calculated using the V ¼ (w 2 Â l)/2 formula.
Invasion assay
The ability of cells to penetrate a basement membrane was assessed using Matrigel invasion chambers (BD) following the manufacturer's instructions. In each chamber of a 24-well plate, 8 Â 10 4 cells were incubated for 24 h. Invasive cells that reached the other side of the membrane were fixed and stained with toluidine blue (Colella et al., 2004) . The membranes were mounted and cells in five randomly chosen fields were counted for each membrane.
Transient transfection and luciferase assay
The USF2-derived pIGF2RLuc reporter gene, USF2, and mutant USF2 expression vectors under the control of the simian virus 40 early promoter have all been previously reported (Luo and Sawadogo, 1996b; Szentirmay et al., 2003) . Cells were seeded 20-24 h prior to transfection in 24-well plates at 3 Â 10 4 cells/well. To each well, 1 ml of FuGene6 transfection reagent (Roche Applied Science) and up to 0.3 mg of plasmid DNA (in quantities noted for each experiment) were added. At 24 h after transfection, the cells were scraped into 60 ml of lysis buffer (25 mM Tris-HCl, pH 7.8, 2 mM dithiothreitol, 2 mM EDTA, 10% glycerol, and 1% Triton X-100). The lysates were spun for 5 min in a microcentrifuge, and the supernatants assayed for luciferase activity using a Monolight 2010 luminometer (Analytical Luminescence Laboratories).
Colony formation assay
Inhibition by USF of colony-forming ability of PC-3 cells was monitored as previously described (Luo and Sawadogo, 1996a) . Cells were seeded in 10-cm dishes at 3 Â 10 5 cells/dish and transfected the following day with either 2 mg of the USF expression vector or the control vector, along with 6 mg of pSV2neo. After 3 weeks of selection in G418 (400 mg/ml), resistant colonies were stained with crystal violet and counted. The experiment was repeated three times.
Immunohistochemistry staining and scoring
Tissue microarray slides of prostate cancer specimens from Cybrdi (Gaithersburg, MD, USA) (42 prostate adenocarcinoma, 10 prostate intraepithelial neoplasia (PIN), and 11 normal prostates) were stained following a standard protocol (Vakar-Lopez et al., 2004) . Deparaffinized sections were incubated in citrate buffer (pH 6.0) for 5 min in a microwave oven at 800 W. Slides were incubated for 24 h at 41C with USF2 antibody (N-18, Santa Cruz, diluted 1:250). Normal rabbit IgG served as negative control. Biotinylated anti-rabbit antibody (Dako Cytomation) at a dilution of 1:500 was used as the secondary antibody. After incubation in avidin-biotin complex solution (Dako), the staining was developed by the diaminobenzidine method, followed by counterstaining with hematoxylin. USF2 expression was scored as negative expression when there was no detectable staining, low expression when the staining was heterogeneous or of low intensity, and high expression when the staining was strong and uniform.
RT-PCR sequencing
Total RNA was extracted from cultured cell lines and primary cultured epithelial cells derived from normal and prostate cancer tissues. For primary culture of prostatic epithelial cells, tissues dissected from radical prostatectomy specimens were processed according to previously described methods (Peehl, 2002) . None of the patients had received prior chemical, hormonal, or radiation therapy. Histological assessment was performed as described (Schmid and McNeal, 1992) . Normal cells were established from tissue with no cancer present in adjacent tissue sections. Cancer cells were established from adenocarcinomas of varying Gleason grade (Peehl, 2002) . Cells in secondary or tertiary passages were used for RNA isolation. cDNA was made from equal amounts of total RNA with the Omniscript Reverse Transcriptase Kit (Qiagen Inc.). Primers for USF2 RT-PCR sequencing were 5 0 -CCCATGGACATG CTGGACCC-3 0 and 5 0 -AACTGGCCTCCAGCCTGCAA-3 0 for 107-696 (590 bp product), and 5 0 -TTGCCTATTTCCCA GCGTCC-3 0 and 5 0 -TCTGTGCTAAGGGCTGGGGA-3 0 for 609-1224 (616 bp product).
Tumor-suppressor role of USF2 in prostate cancer N Chen et al Histological analysis of the prostate gland of USF2 gene knockout mice USF2 knockout mice genotypes were verified by PCR and by Western blotting (Figure 1a ) (Sirito et al., 1998) . USF2-null mice (USF2
À/À
) and control mice (WT (USF2 þ / þ ) of the same background and age) were killed. The reproductive system of male mice was removed and fixed in 10% formaldehyde. All samples were processed by mounting in the same orientation and sectioning in the same direction. Histological slides were stained by hematoxylin and eosin (H&E). Since no evidence showed that any lobe of the mouse prostate is more relevant to human prostate cancer than another lobe (Shappell et al., 2004) , we analysed all prostate ducts in all three lobes.
Statistical analysis
Fisher's test was used to assess the significance of differences of USF2 protein expression among human prostate cancer tissue, PIN, and normal tissue. Tumor sizes in the USF2-expressing vs control groups were compared by two-sided Student's t-test. The average percentage of abnormal prostate ducts in total ducts in USF2-null mice vs WT mice was compared by the Wilcoxon-Mann-Whitney test. P-values less than 0.05 were considered statistically significant.
